Cargando…
“Lazarus response” of nivolumab in a frail patient with non‐small‐cell lung cancer
Lung cancer has aggressive behaviour which often progresses rapidly with disseminated disease and leads to poor performance status (PS) in patients. Because cytotoxic chemotherapy is not recommended under these conditions, there are currently no alternative therapeutic options other than providing s...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322219/ https://www.ncbi.nlm.nih.gov/pubmed/30631445 http://dx.doi.org/10.1002/rcr2.247 |